Adjuvant low-dose rituximab and plasma exchange for acquired TTP

Ítems similars

• Severe primary refractory thrombotic thrombocytopenic purpura (TTP) in the post plasma exchange (PEX) and rituximab era
  per: Goranta, Sowmya, et al.
  Publicat: (2020)
• Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
  per: Hanlon, Ashley, et al.
  Publicat: (2020)
• Rituximab leads to early elimination of circulating CD20(+) T and B lymphocytes in patients with iTTP despite ongoing TPEx
  per: Carden, Marcus A., et al.
  Publicat: (2020)
• OUTCOMES OF PATIENTS WITH WORSENING ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DESPITE DAILY THERAPEUTIC PLASMA EXCHANGE IN THE PHASE 3 HERCULES TRIAL
  per: M. Scully, et al.
  Publicat: (2020-11-01)
• Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab
  per: Abou-Ismail, Mouhamed Yazan, et al.
  Publicat: (2020)